BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20332694)

  • 1. [A case of multidrug-resistant breast cancer associated with multiple hepatic and bone metastases for which cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy proved effective].
    Tanaka T; Tanino H; Hirai I; Hata K; Maebeya S; Oota F; Miki Y
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):511-5. PubMed ID: 20332694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of recurrent breast cancer with life-threatening liver metastasis remarkably responding to classical CMF].
    Hasegawa S; Chishima T; Shimizu D; Ishikawa T; Ichikawa Y
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):507-9. PubMed ID: 20332693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan].
    Nomura Y; Tominaga T; Adachi I; Koyama H; Fukami A
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1949-56. PubMed ID: 8085846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
    Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
    Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
    Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
    J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression.
    Yang W; Klos KS; Zhou X; Yao J; Yang Y; Smith TL; Shi D; Yu D
    Cancer; 2003 Sep; 98(6):1123-30. PubMed ID: 12973835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical controlled trial in advanced breast cancer: CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CMF + T (cyclophosphamide, methotrexate, 5-fluorouracil, tamoxifen). CMEA Cooperative Treatment Group.
    Neoplasma; 1985; 32(3):381-7. PubMed ID: 2862594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ablative hormone therapy and chemotherapy of metastatic breast cancer].
    Kasch R; Gerber B; Blaschke U
    Zentralbl Gynakol; 1989; 111(23):1584-7. PubMed ID: 2560303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of far advanced breast cancer with distant metastases which had mostly disappeared after chemoendocrine therapy].
    Nishimura H; Takasuna K; Kondo R; Hayashi K; Munakata Y; Kasuga Y
    Gan To Kagaku Ryoho; 2000 May; 27(5):753-7. PubMed ID: 10832447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative evaluation of 2 schedules of administration of anti- neoplastic drugs by the CMF protocol in disseminated breast cancer].
    Korman DB; Snimshchikov VA; Dobroskok LB; Maslova IA; Mikaélian SG; Pines EV
    Sov Med; 1991; (3):14-5. PubMed ID: 1882280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Simultaneous radiochemotherapy in locoregional recurrent breast carcinoma after mastectomy. Results in patients with macroscopic residual tumor R2].
    Renner H; van Kampen M
    Strahlenther Onkol; 1994 Aug; 170(8):441-52. PubMed ID: 8085210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential methotrexate and 5-FU in CMFP (cyclophosphamide, methotrexate, 5-FU, and prednisone) therapy for breast cancer.
    Cadman EC; Glick JH; Cross J; Horton J; Taylor SG
    Cancer Treat Rep; 1984 Jun; 68(6):877-9. PubMed ID: 6547367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CMF (cyclophosphamide, methotrexate, ftorafur) chemotherapy in advanced breast cancer].
    Gottwald G; Szakolczai I
    Orv Hetil; 1983 Jan; 124(2):79-84. PubMed ID: 6687491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.